Familial Mediterranean Fever: A Genetic False Alarm and the Old Drug That Quiets It

Growling abdominal pain. Spiking fevers. Aching joints. Then, 24 to 72 hours later, the symptoms disappear as suddenly as they came. No infection. No obvious trigger. For people with Familial Mediterranean Fever (FMF), this cycle can repeat for years before the pattern is finally recognized.

FMF is an autoinflammatory genetic disorder characterized by recurrent episodes of fever and serositis (inflammation of the lining of the abdomen and chest), often accompanied by arthritis. Symptoms typically begin in childhood, with most patients presenting before age 20. 

FMF is not an autoimmune disease, and the distinction matters. In autoimmune conditions, the immune system mistakenly attacks the body's own tissues. In FMF, the innate immune system mistakenly triggers an inflammatory response even when there is no actual threat. 

Left untreated, those repeated inflammatory attacks can have a serious long-term cost. Inflammation raises levels of a protein called serum amyloid A, which, over time, can form deposits in the kidneys. This condition, called AA amyloidosis, can eventually lead to kidney failure.

What Causes FMF?

The recurring inflammation in FMF begins with mutations in the MEFV gene, which provides instructions for making a protein called pyrin. Pyrin is expressed primarily in cells of the innate immune system, including neutrophils and other white blood cells. Normally, pyrin acts as a sensor for certain bacterial toxins that shut down RhoA, a protein that helps regulate the cell's internal machinery. When pyrin detects that RhoA has been shut down, it can assemble a molecular complex called the pyrin inflammasome, which activates caspase-1 and releases IL-1β, a powerful inflammatory signal. In FMF, mutations such as M694V and M680I can make this system abnormally easy to activate, causing it to trigger even when there is no infection, leading to the fever, pain, and swelling of an FMF attack. 

The genetics of FMF are not always straightforward. FMF is traditionally considered an autosomal recessive disease: a person usually needs two mutated copies of MEFV, one from each parent, to develop classic FMF. However, this picture is not absolute. Some single-mutation carriers show elevated inflammation and mild symptoms such as low-grade fevers or joint pain, and a hidden second variant is sometimes found in patients who appear to carry only one. About 10% of people with a clinical diagnosis have no identifiable MEFV mutation. For these patients, diagnosis depends on their symptoms, family history, and overall clinical picture rather than genetic testing alone. 

›

Created in https://BioRender.com

Adapted from Bhatt & Cascella, 2023

Who Does FMF Affect and Why?

FMF is not evenly distributed across populations. It is particularly common among people of Armenian, Turkish, Arab, and non-Ashkenazi Jewish ancestry, with carrier frequencies reported as high as about 1 in 5 in these populations. 

Why did these mutations become so common? One intriguing hypothesis involves Yersinia pestis, the bacterium responsible for plague. Some researchers have proposed that certain MEFV variants may once have helped carriers mount a stronger immune response to infection. If so, variants that offered a survival advantage in the past may also have increased susceptibility to excessive inflammation. However, this evolutionary explanation remains unproven. 

Colchicine: Still the First-Line Answer

For all the sophistication of modern genetics, the main treatment for FMF is very old. Colchicine comes from the autumn crocus, Colchicum autumnale, a plant used in medicine for thousands of years. Today, it remains the standard treatment for preventing FMF attacks and reducing the risk of amyloidosis.

At the molecular level, colchicine binds to tubulin, the protein cells use to build microtubules, and prevents microtubules from assembling. Microtubules act as the cell's internal scaffolding and transport tracks, so disrupting them has several anti-inflammatory effects. Neutrophils, the main inflammatory cells in FMF, depend on microtubules to move toward sites of inflammation and to adhere to blood vessel walls, so colchicine dampens their migration into tissues. Microtubules are also thought to play a role in activating the pyrin inflammasome itself, so colchicine may blunt the IL-1β signal at its source.

For the families living with the disease, colchicine has transformed what was once a potentially devastating condition into a manageable one. But the drug is not perfect. Colchicine has a narrow therapeutic window, gastrointestinal side effects are common in roughly 20% of patients, and only about 40% of patients are fully compliant with dosing. Additionally, 5–10% of patients are resistant to the drug.

Why This Still Matters

FMF sits at an unusual intersection of molecular immunology, evolution, pharmacology, and human history. Yet important questions remain. Some patients have no identifiable MEFV mutation, and others continue to experience inflammation despite colchicine. And while treatments can control the disease, they do not eliminate its underlying genetic cause. For a disease recognized for centuries, and one that continues to affect families across generations, there is still much we do not understand. Studying FMF may not only improve care for those affected but also reveal more about how the immune system distinguishes between danger and its absence.